In treatment-refractory livedoid vasculopathy (LV), a defined escalation protocol applies once the prior treatment line has failed to reach its clinical target. This page outlines the recommended next step after intravenous immunoglobulins (IVIG) have been used and significant pain relief was not achieved.
Intravenous immunoglobulins (IVIG), used for treatment-refractory LV, did not achieve significant pain relief. Failure to reach this target is the escalation trigger for the protocol described here.
The next protocol uses a specific intravenous agent, given at defined intervals, as either complementary treatment or monotherapy in this refractory setting. Its use in LV is off-label. The full regimen — including the agent, schedule, and administration details — is available via the link below.
DOI: 10.1111/ddg.14520
Complementary treatment or monotherapy with iloprost may be considered in treatment-refractory LV (off label).
Case reports have shown good results in ulcer healing with iloprost.
View source ↗